Sorrento Therapeutics, Inc.

382 articles about Sorrento Therapeutics, Inc.

• Sorrento Therapeutics, Inc. Announces Appointment Of George Ng As EVP & Chief Legal Officer

  3/30/2015

• NantWorks And Sorrento Therapeutics, Inc. Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

  3/16/2015

• Sorrento Therapeutics, Inc. To Present At Cowen and Company's 35th Annual Health Care Conference

  2/23/2015

• Sorrento Therapeutics, Inc. To Present At The 17th Annual BIO CEO & Investor Conference

  2/5/2015

• Sorrento Therapeutics, Inc. Announces Retention Of Glen Sato To Provide Strategic Support

  1/30/2015

• Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study

  1/28/2015

• Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study

  1/12/2015

• Conkwest, Sorrento Therapeutics, Inc. And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

  1/6/2015

• Sorrento Therapeutics, Inc. To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

  1/5/2015

• Sorrento Therapeutics, Inc. And Conkwest Announce Exclusive Global Collaboration

  12/19/2014

• Biotech Billionaire Bets $20 Million On Sorrento Therapeutics, Inc.

  12/17/2014

• Sorrento Therapeutics, Inc. Announces Poster Presentations On Its Anti-C-Met/PD-L1 Bispecific Antibodies And Anti-C-Met-Antibody Drug Conjugate At The 37th Annual San Antonio Breast Cancer Symposium

  12/8/2014

• Sorrento Therapeutics, Inc. To Present At The 2014 Oppenheimer Healthcare Conference

  12/5/2014

• Sorrento Therapeutics, Inc. To Present At The 2014 Stifel Healthcare Conference

  11/12/2014

• Sorrento Therapeutics, Inc. Release: Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel

  10/15/2014

• Week In Review: Lee's Pharmaceutical Pays $50 Million For Novel Cancer Drug From Sorrento Therapeutics, Inc.

  10/13/2014

• Sorrento Therapeutics, Inc., Lee's Pharma Forge $49.6 Million Pact

  10/6/2014

• Sorrento Therapeutics, Inc. To Present At Two Healthcare Conferences

  9/5/2014

• Sorrento Therapeutics, Inc. Awarded National Institutes of Health (NIH) Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

  8/26/2014

• Sorrento Therapeutics, Inc. Appoints Douglas Ebersole To Its Board Of Directors

  8/11/2014